Share |

Content about biotechnology

July 17, 2015

Montgomery County has placed its bet on cybersecurity, making some ambitious moves to make sure it's a major player in the young and fast-growing industry, which includes converting a biotechnology incubator in Rockville to become the home of the newly formed National Cybersecurity Center of Excellence (NCCoE).

The NCCoE was created under the National Institute of Standards and Technology (a branch of the U.S. Department of Commerce with a large campus in Gaithersburg) to provide solutions to cybersecurity businesses on a national level.

July 17, 2015

Montgomery County has placed it's bet on cybersecurity, making some ambitious moves to make sure it's a major player in the young and fast-growing industry, that includes converting a biotechnology incubator in Rockville to become the home of the newly formed National Cybersecurity Center of Excellence (NCCoE).

The NCCoE was created under the National Institute of Standards and Technology (a branch of the U.S. Department of Commerce with a large campus in Gaithersburg) to provide solutions to cybersecurity businesses on a national level.

July 17, 2015

Montgomery County has placed it's bet on cybersecurity, making some ambitious moves to make sure it's a major player in the young and fast-growing industry, that includes converting a biotechnology incubator in Rockville to become the home of the newly formed National Cybersecurity Center of Excellence (NCCoE).

The NCCoE was created under the National Institute of Standards and Technology (a branch of the U.S. Department of Commerce with a large campus in Gaithersburg) to provide solutions to cybersecurity businesses on a national level.

January 22, 2015

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company with a primary focus on the creation of therapeutic drugs that treat pulmonary arterial hypertension (PAH). The company has four products on the market with the release of its' fourth drug Orenitram in mid 2014; after receiving FDA approval for it in December 2013.

January 22, 2015

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company with a primary focus on the creation of therapeutic drugs that treat pulmonary arterial hypertension (PAH). The company has four products on the market with the release of its' fourth drug Orenitram in mid 2014; after receiving FDA approval for it in December 2013.

April 4, 2014

If you are a young professional working in Washington, D.C., one thing you’ve probably noticed by now is that there is a fairly large gap between your monthly income and the city’s monthly rent requirements. Not everyone can afford the “luxury” apartments in Foggy Bottom, Georgetown, or Dupont Circle; so what’s a cash-strapped young professional to do?

March 14, 2014

We recently released an article about the Top 5 Worst Markets for Office Space in the D.C. area. Those areas had the highest vacancy rates in the Washington, D.C. area according to a Transwestern report.

Demand for Class-C and Class-B office space is at near all-time lows and at the same time tenants are adamant about leasing Class-A office space. In some sub markets the demand is so great that Class-A office space available is now below 1 percent.

March 14, 2014

We recently released an article about the Top 5 Worst Markets for Office Space in the D.C. area. Those areas had the highest vacancy rates in the Washington, D.C. area according to a Transwestern report.

Demand for Class-C and Class-B office space is at near all-time lows and at the same time tenants are adamant about leasing Class-A office space. In some sub markets the demand is so great that Class-A office space available is now below 1 percent.

February 13, 2014

In the world of commercial office space, a market with a vacancy rate of 10 percent is considered stable; anything below that percentage is to be coveted.  Logically, developers should flock to a market with a low office inventory, especially one with short supply of Class-A office space.  After all, someone is leasing all that space right?

February 7, 2014

Germantown, Maryland is the farthest north of Montgomery County’s commercial centers, it’s also the smallest and youngest in terms of commercial development but that is quickly changing. With approximately 3 million square feet of office space, Germantown has been one of the county’s bright spots in terms of commercial development in the last couple of years.

August 24, 2011

One of the largest and most profitable biotechnology companies in the Mid-Atlantic is trying to increase its revenue by developing an oral form of treatment for pulmonary arterial hypertension (PAH).

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) released its FREEDOM-C(2) Phase 3 clinical trial results today but the company announced that the study did not meet its primary endpoint.

August 24, 2011

One of the largest and most profitable biotechnology companies in the Mid-Atlantic is trying to increase its revenue by developing an oral form of treatment for pulmonary arterial hypertension (PAH).

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) released its FREEDOM-C(2) Phase 3 clinical trial results today but the company announced that the study did not meet its primary endpoint.

August 16, 2011

Rockville-based Nabi Biopharmaceuticals (Nasdaq:NABI) has added to its cash stockpile by obtaining $5 Million in milestone payments from Fresenius USA Manufacturing, Inc.

August 11, 2011

Two Rockville-based firms involved in drug development have teamed up to develop a new Tuberculosis (TB) vaccine.

Aeras a non-profit focused on developing vaccines to prevent TB and Emergent BioSolutions a biotechnology firm mostly known for its Antrax drug--BioThrax--are now entering a Phase IIb Proof-of-Concept Trial of Emergent's Modified Vaccinia virus Ankara--Antigen 85Abased TB vaccine.

August 11, 2011

Two Rockville-based firms involved in drug development have teamed up to develop a new Tuberculosis (TB) vaccine.

Aeras a non-profit focused on developing vaccines to prevent TB and Emergent BioSolutions a biotechnology firm mostly known for its Antrax drug--BioThrax--are now entering a Phase IIb Proof-of-Concept Trial of Emergent's Modified Vaccinia virus Ankara--Antigen 85Abased TB vaccine.

August 11, 2011

Two Rockville-based firms involved in drug development have teamed up to develop a new Tuberculosis (TB) vaccine.

Aeras a non-profit focused on developing vaccines to prevent TB and Emergent BioSolutions a biotechnology firm mostly known for its Antrax drug--BioThrax--are now entering a Phase IIb Proof-of-Concept Trial of Emergent's Modified Vaccinia virus Ankara--Antigen 85Abased TB vaccine.

July 21, 2011

The largest biotech in the Baltimore-Washington area measured by market value said Benlysta is gaining momentum in net sales

After more than a decade of research, development, and waiting more than a year for a delayed FDA approval, Human Genome Sciences, Inc (NASDAQ: HGSI) finally has a drug on the market that it can consistently sell to the healthcare industry.

The Rockville, Md biotechnology company reported Benlysta net sales of $7.8 Million. $1.2 Million in additional sales were excluded due to non-delivery to healthcare providers prior to the release of second quarter financial results.

Increasing Lupus Drug Sales

July 21, 2011

The largest biotech in the Baltimore-Washington area measured by market value said Benlysta is gaining momentum in net sales

After more than a decade of research, development, and waiting more than a year for a delayed FDA approval, Human Genome Sciences, Inc (NASDAQ: HGSI) finally has a drug on the market that it can consistently sell to the healthcare industry.

The Rockville, Md biotechnology company reported Benlysta net sales of $7.8 Million. $1.2 Million in additional sales were excluded due to non-delivery to healthcare providers prior to the release of second quarter financial results.

Increasing Lupus Drug Sales

June 27, 2011

The Chinese Biopharmaceutical Association held its annual event Sunday at the University System of Maryland, Shady Grove Campus in Rockville.

The 16th annual event for the association was represented by a large number of executives from China as well as the United States. The organization's members include scientists, attorneys, entrepreneurs and other professionals. More than four delegations in groups of ten or more attended the event, flying all the way from China.

June 27, 2011

The Chinese Biopharmaceutical Association held its annual event Sunday at the University System of Maryland, Shady Grove Campus in Rockville.

The 16th annual event for the association was represented by a large number of executives from China as well as the United States. The organization's members include scientists, attorneys, entrepreneurs and other professionals. More than four delegations in groups of ten or more attended the event, flying all the way from China.

June 27, 2011

The Chinese Biopharmaceutical Association held its annual event Sunday at the University System of Maryland, Shady Grove Campus in Rockville.

The 16th annual event for the association was represented by a large number of executives from China as well as the United States. The organization's members include scientists, attorneys, entrepreneurs and other professionals. More than four delegations in groups of ten or more attended the event, flying all the way from China.

June 16, 2011

Despite recession, several Maryland Biotechs turn a profit

Biotechnology firms have been reported to be hard hit by the recent recession; struggling to stay afloat amid a dearth of venture capital funding and and lack of new drugs selling on the market. The Biotech industry is often pigeonholed as frail, cash strapped and high risk; spending years on research to develop drugs but often ending with failure and bankruptcy.

But in Maryland it's a different story. Several biotech firms have achieved profitability for their full fiscal year and some of them for the first time in the midst of a troubled U.S. economy.

June 16, 2011

Despite recession, several Maryland Biotechs turn a profit

Biotechnology firms have been reported to be hard hit by the recent recession; struggling to stay afloat amid a dearth of venture capital funding and and lack of new drugs selling on the market. The Biotech industry is often pigeonholed as frail, cash strapped and high risk; spending years on research to develop drugs but often ending with failure and bankruptcy.

But in Maryland it's a different story. Several biotech firms have achieved profitability for their full fiscal year and some of them for the first time in the midst of a troubled U.S. economy.

June 16, 2011

Despite recession, several Maryland Biotechs turn a profit

Biotechnology firms have been reported to be hard hit by the recent recession; struggling to stay afloat amid a dearth of venture capital funding and and lack of new drugs selling on the market. The Biotech industry is often pigeonholed as frail, cash strapped and high risk; spending years on research to develop drugs but often ending with failure and bankruptcy.

But in Maryland it's a different story. Several biotech firms have achieved profitability for their full fiscal year and some of them for the first time in the midst of a troubled U.S. economy.